AM 112

Drug Profile

AM 112

Alternative Names: AM-112

Latest Information Update: 05 Jul 2010

Price : $50

At a glance

  • Originator Amura; Micron Research
  • Class Antibacterials; Oxapenems; Small molecules
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 05 Jul 2010 AM 112 is still in preclinical development in United Kingdom
  • 16 Feb 2006 AM 112 is available for licensing (http://www.amura.co.uk)
  • 16 Feb 2006 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top